The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst)
Exploratory ctDNA analyses for the EVOKE-1 study in metastatic non-small cell lung cancer (mNSCLC).
 
Enriqueta Felip
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Daiichi Sankyo Europe GmbH; Gilead Sciences; GlaxoSmithKline; ITeos Therapeutics; Johnson & Johnson/Janssen; Merck Sharp & Dohme; Novartis; Pfizer; Pierre Fabre; Regeneron; Roche; Turning Point Therapeutics
Speakers' Bureau - Amgen; AstraZeneca; Bristol Myers Squibb; Daiichi Sankyo; Genentech; Gilead Sciences; Johnson & Johnson/Janssen; Lilly; Medical Trends; Medscape; Merck Serono; Merck Sharp & Dohme; Novartis; Peervoice; Pfizer; Regeneron; Roche
Travel, Accommodations, Expenses - AstraZeneca; Janssen; Roche
Other Relationship - GRIFOLS
(OPTIONAL) Uncompensated Relationships - "ETOP IBCSG Partners" Member of the Scientific Committee; “Medical writing assistance for this abstract was provided by Nimisha H. Bhoola, PhD, of Nucleus Global, an Inizio Company, and funded by F. Hoffmann-La Roche Ltd.”; Member of the Scientific Advisory Committee -Hospital Universitari Parc Taulí-; SEOM (Sociedad Española de Oncología Médica), President from 2021-2023
 
Peiwen Kuo
Stock and Other Ownership Interests - Gilead Sciences
 
Pilar Garrido
Employment - Teva (I)
Consulting or Advisory Role - Amgen; AstraZeneca; BeiGene; Daiichi Sankyo Europe GmbH; Gebro Pharma (I); IO Biotech; Janssen Oncology; MSD Oncology; Nordic Group (I); Pfizer; PharmaMar; Pierre Fabre; Regeneron; Roche Pharma AG
Speakers' Bureau - Amgen; AstraZeneca; Daiichi Sankyo Europe GmbH; Johnson & Johnson/Janssen; Lilly; Pfizer
Travel, Accommodations, Expenses - AstraZeneca Spain; Johnson & Johnson/Janssen; Roche Pharma AG
Other Relationship - IO Biotech; Janssen Oncology; Novartis
 
Christos Chouaid
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Janssen Oncology; MSD; Novartis; Pfizer; Roche; Takeda
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; MSD; Roche
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Janssen medical Affairs; MSD (Inst); Novartis (Inst); Pfizer (Inst); Pierre Fabre (Inst); Roche (Inst); Takeda (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Pfizer; Roche
 
Yvonne Summers
Honoraria - Abbvie; Amgen; AstraZeneca; Bristol-Myers Squibb; Lilly; MSD; Roche; Takeda
Other Relationship - Roche; Takeda
 
Marcello Tiseo
No Relationships to Disclose
 
Shan Tang
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Linda Su-Feher
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Riddhi Patel
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
Travel, Accommodations, Expenses - Gilead Sciences
 
Sabeen Mekan
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
 
Juliane Jürgensmeier
Employment - Gilead Sciences
Stock and Other Ownership Interests - Gilead Sciences
Travel, Accommodations, Expenses - Gilead Sciences
 
Giannis Mountzios
Honoraria - Amgen; AstraZeneca; BMS GmbH & Co. KG; Boehringer Ingelheim; MSD; Novartis; Roche; Takeda
Consulting or Advisory Role - Amgen; AstraZeneca/Greece; BMS GmbH & Co. KG; MSD; Novartis; Roche; Takeda
Speakers' Bureau - AstraZeneca
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; BMS GmbH & Co. KG; Demo Pharmaceutical; Ipsen; MSD; Novartis; Roche